Oncology drug marketers 'missing out' online: study

Share this article:
Oncology drug e-marketers are missing out on major opportunities to grow their brands by failing to consider the divergent information requests of doctors, patients and key opinion leaders visiting cancer treatment Web sites, according to healthcare information and consulting firm Best Practices.

“We have found there are significant gaps between the information requested by physicians, key opinion leaders (KOLs) and patients, versus what was being presented on oncology Web sites,” said Jon Easter, Best Practices' executive director of pharmaceutical research. “With those gaps, there are greater opportunities for companies [with which to take advantage].”

A recent study from Easter's firm, titled “Using Oncology Websites to Build Brand Equity and Loyalty,” shows just how different the priorities of doctors and patients in the oncology category are.
For example, 80% of patients surveyed said it was not important to have discussion space on an oncology brand Web sites, while 80% of physicians and KOLs said it was.

Easter's advice for the problem? “Oncology drug marketers must align their Web site strategies with their products and corporate branding,” he says, explaining that e-marketers early to adopt are already seeing greater brand growth within the category.

Easter says centralized oncology Web sites are “a trend that is moving slower than everybody would hope, since the regulatory environment puts up obstacles. Some companies are better at navigating those obstacles than others.”

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...